MEMORANDUM AND ORDER
This action is before the Court on the Motion to Remand brought by Plaintiffs Barbara Rutherford, Edward Miechle, Rachel Garza, Beth Renee Brodhacker, Sandra Zola, Thomas Vogel, Tom Benhoff, Emil Smith, Connie Testa, and Darrell Lane (Doc. 18). For the following reasons, the motion is GRANTED.
Introduction
Plaintiffs originally filed this action in the Circuit Court for the Third Judicial Circuit, Madison County, Illinois, asserting claims based upon strict products liability, negligence, consumer fraud, common-law fraud, and breach of warranty arising from personal injuries allegedly caused by Vioxx, a prescription pain medication manufactured by Defendant Merck & Co. (“Merck”). Merck subsequently removed the action to this Court, asserting that Defendants Walgreen Co. (“Walgreens”) and American Drug Stores, Inc. (“Oseo Drugs”), who are, like Plaintiffs, citizens of Illinois, have been fraudulently joined to defeat federal diversity jurisdiction. Plaintiffs have requested remand of the action to Illinois state court for lack of subject matter jurisdiction.
At issue here are Count III, Count VI, and Count XI of Plaintiffs’ complaint, which assert, respectively, claims for sale of a defective product sounding in strict products liability, negligent failure to warn, and breach of warranty against Walgreens and Oseo Drugs. More specifically, Plaintiffs’ complaint alleges that Walgreens and Oseo Drugs filled prescriptions for Vioxx for Plaintiff Barbara Rutherford and that Oseo Drugs filled prescriptions for Vioxx for Plaintiff Edward Miechle. Merck contends that Plaintiffs have fraudulently joined Walgreens and Oseo Drugs because Plaintiffs’ claims against those *845 parties are barred by the “learned intermediary” doctrine under Illinois law. Also, Merck contends that under Illinois law a sale of prescription medication does not constitute a sale of “goods” for purposes of Article 2 of the Illinois Uniform Commercial Code (“Illinois UCC”). Finally, Merck contends that the claims in this case are procedurally misjoined so as to amount to fraudulent joinder. The Court will address each of these contentions in turn.
Discussion
A. Merck’s Request for a Stay
In opposing Plaintiffs’ request for remand, Merck urges the Court to stay proceedings in this action pending transfer of the action by the Judicial Panel on Multidistrict Litigation (“JPML”) for coordinated or consolidated pretrial proceedings.
See
28 U.S.C. § 1407. As Merck acknowledges, the Court retains full jurisdiction over this action until such time as a transfer order by the JPML is filed in the office of the clerk of the district court of the transferee district, in this instance the United States District Court for the Eastern District of Louisiana.
See Illinois Mun. Retirement Fund v. Citigroup, Inc.,
In
Meyers v. Bayer AG,
Third, the
Meyers
court concluded, considerations of judicial economy dictate that a court conduct at least limited review of a remand motion before granting a stay: “If the limited review reveals that the case is a sure loser in the court that has jurisdiction (in the conventional sense) over it, then the [transferor] court ... should dismiss the case rather than waste the time of another court.”
The
Meyers
court concluded that, when faced by a request for a stay while a
*846
challenge to jurisdiction is pending, “a court’s first step should be to make a preliminary assessment of the jurisdictional issue.”
B. Plaintiffs’ Motion to Remand
1. Legal Standard
Removal based on diversity requires that the parties be of diverse state citizenship and that the amount in controversy exceed $75,000.
See
28 U.S.C. § 1332;
Id.
§ 1441. The party seeking removal has the burden of establishing federal jurisdiction.
See Doe v. Allied-Signal, Inc.,
In evaluating diversity of citizenship, a court must disregard a defendant that has been fraudulently joined.
See Schwartz v. State Farm Mut. Auto. Ins. Co.,
2. Plaintiffs’ Claims for Strict Products Liability and Negligence Against Walgreens and Oseo Drugs
As discussed, Merck argues that Count III and Count VI of Plaintiffs’ complaint, which assert claims for strict products liability and negligence against Walgreens and Oseo Drugs, are barred by the “learned intermediary” doctrine under Illinois law. The learned intermediary doctrine, which applies to both negligence and strict liability claims, provides that, where a manufacturer of a prescription drug provides adequate warning to physicians of the drug’s known dangerous propensities, the manufacturer and pharmacists dispensing the drug are relieved of a duty to warn the drug’s potential users; instead, the physicians, using their medical judgment, have a duty to convey the warnings to their patients.
See Kirk v. Michael Reese Hosp. & Med. Ctr.,
In this instance Plaintiffs specifically have pleaded a well established exception to the learned intermediary doctrine for cases in which a pharmacy is aware of a patient’s health history, yet dispenses to the patient a contraindicated drug. In
Happel v. Wal-Mart Stores, Inc.,
The scope of the Court’s inquiry at this juncture is extremely narrow, namely, to determine whether, after resolving all issues of fact and law in Plaintiffs’ favor, Plaintiffs have stated a claim against Walgreens and Oseo Drugs upon which relief can be granted in Illinois state court.
See Simmons v. Norfolk S. Ry. Co.,
In evaluating a claim of fraudulent joinder a court may in some circumstances “pierce the pleadings.”
CC Indus., Inc. v. ING/ReliaStar Life Ins. Co.,
No. 03 C 2075,
In
Smallwood v. Illinois Central Railroad Co.,
The Court finds that Merck’s allegations of fraudulent joinder based on the learned intermediary doctrine fail for an additional reason. Under Illinois law, to claim the protection of the learned intermediary doctrine, a defendant must be able to show that physicians received adequate warning of the known dangerous propensities of a prescription drug. In
Proctor v. Davis,
Plaintiffs’ complaint in this case alleges that Merck failed to warn physicians of the adverse effects of Vioxx. To cite a few examples:
The Vioxx manufactured and supplied by Merck was unaccompanied by proper and adequate warnings regarding all adverse side effects associated with the use of Vioxx, and the comparative severity and duration of the adverse effects. The warnings given by Merck did not accurately reflect the symptoms, type, scope or severity of the side effects.
* % * i’fi * ❖
Merck also failed to effectively warn users and physicians that numerous other methods of pain relie[f], including Ibuprofen, Naproxen, and/or aspirin were safer.
jf; íJí ifc :¡< sji sfc
Merck failed to give adequate post-marketing warnings or instructions for the use of Vioxx because after Merck knew or should have known of the risk of injury from Vioxx use, Merck failed to provide adequate warnings to users or consumers and continued to aggressively promote the product to doctors, hospitals, and directly to consumers.
Compl. ¶ 58, ¶¶ 61-62. In fact, the complaint alleges active fraud by Merck in concealing adverse health effects of Vioxx from physicians: “Merck communicated the purported benefits of Vioxx, while failing to disclose the serious and dangerous side effects related to the use of its product, and in fact actually concealing from health care providers the adverse cardiovascular effects of Vioxx.”
Id.
¶ 93. In light of these allegations, the applicability of the learned intermediary doctrine in this case clearly presents issues of fact that the Court must resolve in favor of Plaintiffs and in favor of remand to state court.
See Poulos,
As a final matter, the Court expresses considerable skepticism about whether the learned intermediary doctrine is a proper basis for a claim of fraudulent joinder at all, given that the defense implicates issues about foreseeability and causation germane to the liability of both Merck and the diversity-defeating defendants. The Court has explained previously that a claim of fraudulent joinder that “indicated] that the plaintiffs case [is] ill-founded as to all the defendants” is one which “manifestly [goes] to the merits of the action as an entirety, and not to the joinder” and is “not such as to require the state court to surrender its jurisdiction.”
Simmons,
3. Fraudulent Misjoinder
Finally, Merck argues that the claims in this case are “fraudulently misjoined,” relying upon
Tapscott v. MS Dealer Service Corp.,
The United States Court of Appeals for the Seventh Circuit has not had occasion to pass on the validity of the doctrine of “fraudulent misjoinder” crafted in
Tapscott.
This Court gives respectful consideration to decisions of courts of appeals in sister circuits, see
Colby v. J.C. Penney Co.,
Furthermore, the federal courts traditionally have held that matters of state civil procedure, including, presumably, joinder of parties and claims, have no bearing on the existence or nonexistence of federal subject matter jurisdiction in a given case. For example, in
Shamrock Oil & Gas Corp. v. Sheets,
But at the outset it is to be noted that decision turns on the meaning of the removal statute and not upon the characterization of the suit or the parties to it by state statutes or decisions. The removal statute which is nationwide in its operation, was intended to be uniform in its application, unaffected by local law definition or characterization of the subject matter to which it is to be applied. Hence the Act of Congress must be construed as setting up its own criteria, irrespective of local law, for determining in what instances suits are to be removed from the state to the federal courts.
Id.
at 104,
*852
In the Court’s view, the
Tapscott
doctrine is an improper expansion of the scope of federal diversity jurisdiction by the federal courts.
See In re Norplant Contraceptive Prods. Liab. Litig.,
As the Seventh Circuit Court of Appeals has observed many times, most recently in
Knudsen v. Liberty Mutual Insurance Co.,
The reasons underlying the policy favoring simple, easy-to-apply jurisdictional rules are obvious. First, it is, by definition, harmful to federalism and a plaintiffs presumptive right to choose his or her forum for federal courts to exercise jurisdiction they do not possess.
See Klein v. Vision Lab Telecomms., Inc.,
The Court’s review of the caselaw regarding the fraudulent misjoinder doctrine that has emerged in the ten years since Tapscott was decided discloses enormous judicial confusion engendered by the doc-
*853
trine. For example, a number of courts, applying
Tapscott,
have held that mere misjoinder gives rise to removal jurisdiction.
See, e.g., Burns v. Western S. Life Ins. Co.,
Also, even among those courts that accept “egregious” misjoinder as the predicate to application of the
Tapscott
doctrine, no clear definition of “egregiousness” has emerged.
See, e.g., Walton v. Tower Loan of Miss.,
Many, courts have foundered on shoals of tautology in trying to define fraudulent misjoinder.
See, e.g., Walton,
A number of courts seem to have adopted the view that egregious misjoinder is tested by whether there is a reasonable probability that a state court would find proper joinder.
See, e.g., Moore v. Smith-Kline Beecham Corp.,
First, under the law of this Circuit, a case removed from state court to federal court becomes, “when it arrive[s] there, ... subject to the same rules of procedure as if it had been originally sued in [federal] court.”
Grivas v. Parmelee Transp. Co.,
Finally, just as no clear standards for the application of the
Tapscott
doctrine have emerged, the Court predicts that no such standards will emerge. The Court is well aware from its experience that determinations about proper joinder are of necessity highly discretionary, involving intensely case-specific decisions about the fairest and most economical way to adjudicate particular claims.
See Intercon Research Assocs., Ltd. v. Dresser Indus., Inc.,
Conclusion
For the foregoing ■ reasons, Plaintiffs’ Motion to Remand (Doc. 18) is GRANTED. Pursuant to 28 U.S.C. § 1447(c), this action is REMANDED to the Circuit Court for the Third Judicial Circuit, Madison County, Illinois, for lack of federal subject matter jurisdiction. The Motion to Stay brought by Defendant Merck & Co. (Doc. 4), the Motion to Sever brought by Defendant Merck & Co. (Doc. 5), the Motion to Dismiss brought by Defendant American Drug Stores, Inc. (Doc. 10), and the Motion to Dismiss brought by Defendant Walgreen Co. (Doc. 15) are DENIED as moot.
IT IS SO ORDERED.
Notes
. Having determined that Plaintiffs have asserted viable claims against the non-diverse defendants for strict products liability and negligence, the Court need not determine whether they have viable claims for breach of warranty also. Were the Court to reach the issue, however, the Court likely would decide that the issue presents an ambiguous question of state law that must be resolved in favor of remand. Merck’s contention that the transactions at issue in this case do not involve "goods” within the meaning of Article 2 of the Illinois UCC is based upon
Brandt v. Boston Scientific Corp.,
. Not the least of the confusion created by
Tapscott
is an ongoing debate among federal courts about whether egregious misjoinder is tested using federal or state procedural rules.
See, e.g., In re Silica Prods. Liab. Litig.,
